The Global Epigenetics Market is expected to reach US$ 2,611.57 Mn in 2025 from US$ 991.45 in 2017 and estimated to grow with a CAGR of 13.6% from 2018-2025.
The market for epigenetics is expected to grow as declining prices of sequencing, increasing prevalence of cancer, funds & grants provided by government bodies are expected to fuel the market growth during the forecast period. In addition, promising precise treatments by neurogenetics are likely to have a positive impact on the growth of the market in the coming years.
Global epigenetics market, based on technology was segmented histone modification, DNA methylation and other technologies. In 2017, DNA methylation segment held the largest share of the market, by technology. The largest share of the DNA methylation is primarily owing to its ability to develop therapies for diseases including cancer, lupus, muscular dystrophy and various congenital defects and also it helps to prevent conditions that develop during embryonic development such as, abnormal methylation of the X-chromosome and gene imprinting.
DNA methylation Segment is expected to grow the Market for Epigenetics over the Forecast Period for Technology Segment.
The major players operating in the epigenetics market are Merck KGaA, Thermo Fisher Scientific Inc., ABCAM Plc, Agilent Technologies, Active Motif, Qiagen, Bio-Rad Laboratories, Inc., Perkinelmer Inc., New England Biolabs (NEB), and Illumina Inc. For instance, in February, 2018, QIAGEN launches epigenetic breast cancer test in Europe. It is the first clinically validated DNA methylation assay that helps predict the response to anthracycline-based chemo by certain high-risk breast cancer patients.
The objective of the study is to describe, define, and forecast the epigenetics market by technology, product, application, end user and region. The report also provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and trends). The report helps to analyze market with respect to individual growth trends, prospects, and contributions to the overall market.
The study of heritable changes in gene expression that do not involve changes to the underlying DNA sequence is known as epigenetics. A single or multiple change in phenotype without a changing the genotype which results affects the cells that can read the genes. The report would be of an interest to various stakeholders operating in the epigenetics market. These stakeholders include hospitals, research institutes, medical device suppliers, diagnostic centers, academic institutes, market research, equipment manufacturers, and consulting firms.
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Media, Healthcare and Telecommunication industries.